Full-Time

Director GPV Compliance & Business Management

QA

Updated on 7/25/2026

 Otsuka Pharmaceutical

Otsuka Pharmaceutical

1,001-5,000 employees

Global pharmaceutical company developing medicines

Compensation Overview

$186.5k - $278.9k/yr

+ Incentive

Princeton, NJ, USA

In Person

Category
QA & Testing (1)
Required Skills
Google Cloud Platform

Get referred to Otsuka Pharmaceutical

Find people who can refer or advise you

Requirements
  • Bachelor's degree is required
  • Experience working in a global setting
  • Experience in managing vendor relationships and oversight
  • Minimum of 6 years PV Compliance or Quality Management experience in the pharmaceutical industry or relevant leadership experience
  • Microsoft proficient
  • Experience with GVP, GCP, inspections conducted by FDA, MHRA, etc.
  • Experience with quality compliance management systems
  • Knowledge of ICH, US and EU regulations and requirements for pharmacovigilance
  • Solid background and experience in pharmaceutical quality system management (GxP)
Responsibilities
  • Provide strategic leadership and oversight of Global Pharmacovigilance (GPV) audit and inspection preparedness, ensuring a state of continuous readiness across all regions in partnership with Local Safety Managers and key global stakeholders
  • Direct the global strategy, governance, and execution of GxP regulatory inspections impacting PV, ensuring alignment with Global Quality and driving resolution through to closure with a strong focus on regulatory excellence
  • Oversee the planning, resourcing, and strategic coordination of Global Quality audits affecting affiliates for PV, global PV processes, and alliance company activities, ensuring effective global support and timely audit closure
  • Lead the governance of alliance company and Global Service Provider PV audit activities, ensuring compliance with contractual obligations, performance expectations, and global PV quality standards
  • Serve as a senior liaison with Inspectorates, Regulatory Agencies, industry associations, and inter-company networks to anticipate regulatory trends, benchmark PV inspection practices, and influence best practices
  • Provide strategic direction and escalation support to Local Safety Managers (LSMs) across all PV-related audit and inspection activities to ensure consistent global compliance
  • Drive global readiness, strategic planning, and post-inspection remediation for GPV audits and inspections, ensuring oversight of CAPA development, implementation, and long-term mitigation strategies
  • Oversee the audit and inspection governance framework for key collaborating companies, ensuring adherence to compliance expectations, risk mitigation, and ongoing quality performance management
  • Provide strategic oversight for the development and delivery of departmental training programs that strengthen inspection readiness, advance PV quality culture, and support continuous improvement initiatives
  • Lead enterprise-wide initiatives to optimize PV processes for reliability, effectiveness, and operational efficiency, driving continuous improvement and innovation
  • Oversee and guide root cause analysis and investigations into non-adherence to PV requirements, ensuring strategic risk mitigation, sustainable corrective actions, and systemic prevention
  • Provide strategic leadership and oversight across Otsuka GPV functions to ensure the effective development, prioritization, and governance of PV-related CAPAs resulting from internal quality audits and regulatory inspections
  • Lead and guide CAPA owners through complex investigations, ensuring rigorous root‑cause analysis, impact assessment, and timely, high‑quality PV-related CAPA closure
  • Partner at a senior level with Global Quality to ensure globally aligned, timely, and regulatory‑compliant audit and inspection responses, while driving clear accountability and ownership among PV SMEs worldwide
  • Oversee and accelerate the closure of PV-related CAPAs and audit findings—internal and external—ensuring strategic remediation, risk mitigation, and sustainable quality improvements across the PV system
  • Provide executive oversight of PV‑related CAPA development, management, and metrics tracking, including evaluation of audit/inspection findings to identify systemic trends and opportunities for improvement
  • Review and approve PV-related CAPA records at key stages of the lifecycle to ensure compliance with global procedures, adequacy of documentation, and alignment with regulatory expectations
  • Oversee the governance, prioritization, and cross‑functional coordination of PV‑related Deviations, Temporary Change Controls (TCCs), and Standalone CAPAs, ensuring robust quality and compliance controls
  • Lead regular governance meetings with Global Quality, establishing best practices, driving cross‑functional alignment, managing escalations, and ensuring a proactive and inspection‑ready PV quality culture
  • Attend Global / Regional meetings as required
  • Present compliance metrics at Global Meetings
  • Contribute to maintenance of PV System Master File as required
  • May be assigned to lead or assist with special projects or process development
  • Collaborate with the Regional PV offices for process improvement initiatives and corrective and preventive actions identified by the Regional PV offices
  • May perform any other duties as needed.
 Otsuka Pharmaceutical

Otsuka Pharmaceutical

View

Otsuka Pharmaceutical is a global health-focused company that develops and markets medicines and nutraceutical products. It creates pharmaceuticals like Abilify (aripiprazole), an antipsychotic, and consumer health brands such as Pocari Sweat, an ion-replacement drink. Its products work by medical mechanisms (Abilify modulates dopamine and serotonin receptors to treat psychiatric conditions) and by supporting hydration and electrolyte balance (Pocari Sweat). Otsuka differentiates itself through a long, international growth path from its roots as a Japanese chemical manufacturer, a balanced portfolio spanning prescription drugs and health beverages, and a philosophy of developing new products to improve health worldwide. Its goal is to deliver healthier outcomes for people around the world by expanding access to innovative medicines and health-related consumer products.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • 4D-150 Phase 3 data showed sustained efficacy and strong APAC commercialization potential.
  • VOYXACT advances Otsuka’s nephrology franchise with accelerated U.S. approval and confirmatory readouts.
  • Japan reimbursement for Paradise renal denervation supports a new resistant-hypertension market entry.

What critics are saying

  • 4D-150 requires successful Phase 3 outcomes before Otsuka monetizes its APAC rights.
  • Accelerated approval leaves VOYXACT exposed to confirmatory-trial failure and withdrawal risk.
  • Device and digital hypertension products face slow physician adoption and reimbursement friction in Japan.

What makes Otsuka Pharmaceutical unique

  • Otsuka combines psychiatry, rare disease, and device distribution under one global platform.
  • Its 4D-150 Asia-Pacific license extends gene therapy reach into retinal vascular diseases.
  • Otsuka pairs internal development with external licensing across Japan, China, Australia, and Oceania.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
SonoThera, Inc.
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.

The Associated Press
Mar 25th, 2026
Otsuka's Voyxact shows 82.5% hematuria improvement in IgA nephropathy trial at 48 weeks

Otsuka presented new Phase 3 VISIONARY trial data for VOYXACT (sibeprenlimab-szsi) in IgA nephropathy patients at the 2026 ISN World Congress of Nephrology. The analyses showed 82.5% of patients receiving sibeprenlimab achieved negative microscopic hematuria at week 48, compared with 52.6% on placebo. Median time to achieve hematuria negativity was nine weeks versus 24 weeks for placebo. VOYXACT, approved under accelerated approval in the US, is a monoclonal antibody that inhibits APRIL, a key driver in IgAN pathogenesis. Previously reported data showed the drug met its primary endpoint with a 51.2% placebo-adjusted reduction in proteinuria at nine months. The trial continues evaluating sibeprenlimab's effect on preserving kidney function over 24 months.

Business Wire
Mar 2nd, 2026
Paradise ultrasound renal denervation system now covered by insurance in Japan for resistant hypertension

Otsuka Medical Devices and Otsuka Pharmaceutical have launched the Paradise Ultrasound Renal Denervation system in Japan, with National Health Insurance coverage effective 1 March. The device, developed by US subsidiary Recor Medical, treats resistant hypertension by reducing sympathetic nerve overactivity surrounding renal arteries. The system targets patients whose blood pressure remains above target despite using three different antihypertensive medications, including a diuretic. This marks Japan's first ultrasound renal denervation treatment. The Paradise system received FDA approval in the US in November 2023. Under a co-promotion agreement, both Otsuka companies will leverage their cardiovascular and renal expertise to deliver the treatment according to guidelines established by Japanese medical societies. The system offers a new option for resistant hypertension patients at high risk of serious cardiovascular complications.